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Abstract
Background—We aimed for a comprehensive delineation of genetic, functional and phenotypic 
aspects of GRIN2B encephalopathy and explored potential prospects of personalised medicine.
Methods—Data of 48 individuals with de novo GRIN2B variants were collected from several 
diagnostic and research cohorts, as well as from 43 patients from the literature. Functional 
consequences and response to memantine treatment were investigated in vitro and eventually 
translated into patient care.
Results—Overall, de novo variants in 86 patients were classified as pathogenic/likely 
pathogenic. Patients presented with neurodevelopmental disorders and a spectrum of hypotonia, 
movement disorder, cortical visual impairment, cerebral volume loss and epilepsy. Six patients 
presented with a consistent malformation of cortical development (MCD) intermediate between 
tubulinopathies and polymicrogyria. Missense variants cluster in transmembrane segments and 
ligand-binding sites. Functional consequences of variants were diverse, revealing various potential 
gain-of-function and loss-of-function mechanisms and a retained sensitivity to the use-dependent 
blocker memantine. However, an objectifiable beneficial treatment response in the respective 
patients still remains to be demonstrated.
Conclusions—In addition to previously known features of intellectual disability, epilepsy and 
autism, we found evidence that GRIN2B encephalopathy is also frequently associated with 
movement disorder, cortical visual impairment and MCD revealing novel phenotypic 
consequences of channelopathies.
Correspondence to: Dr Johannes R Lemke, Institute of Human Genetics, University of Leipzig, Leipzig, Germany; 
johannes.lemke@medizin.uni-leipzig.de. 
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INTRODUCTION
N-methyl-D-aspartate receptors (NMDAR) are ligand-gated ion channels expressed 
throughout the brain mediating excitatory neurotransmission. Signalling via NMDAR plays 
an important role in brain development, learning, memory and other higher cognitive 
functions. NMDAR are di-heterotetramers or triheterotetramers composed of two glycine-
bindingGluN1(encodedbyGRIN1)andtwo glutamate-binding GluN2 subunits (GRIN2A-D).1 
Simultaneous binding of both agonists activates the NMDAR, which opens a cation-selective 
pore leading to an influx of Ca2+ and depolarisation. Compared with the ubiquitously 
expressed GluN1 subunit, the GluN2 subunits show specific spatiotemporal expression 
profiles throughout the central nervous system.2 GluN2B and GluN2D subunits are 
expressed prenatally, whereas expression of GluN2A and GluN2C significantly increases 
shortly after birth. Over time, postnatal expression of GluN2B becomes progressively 
restricted to the forebrain.
Pathogenic de novo variants in four genes encoding NMDAR subunits (GRIN1, GRIN2A, 
GRIN2B and GRIN2D) have been identified in patients with neurodevelopmental disorders 
comprising developmental delay (DD), intellectual disability (ID), autism spectrum 
disorders (ASD), epilepsy and epileptic encephalopathy, as well as movement disorders such 
as choreoathetosis or dystonia.3–13
To delineate the phenotypic spectrum of GRIN2B encephalopathy, we reviewed previously 
published and newly diagnosed patients with pathogenic/likely pathogenic de novo variants 
in GRIN2B. We evaluated the functional consequences of 16 variants in Xenopus laevis 
oocytes, investigated in vitro responses to memantine for six potential gain-of-function 
variants and aimed for translation of these results into personalised therapeutic approaches.
MATERIALS AND METHODS
Patients
We reviewed the clinical and genetic data of patients in whom GRIN2B de novo variants 
were detected within diagnostic or research settings focusing on neurodevelopmental 
disorders. Referring physicians provided detailed clinical information via a standardised 
clinical questionnaire. Molecular diagnostics were performed by targeted panel 
sequencing,14 whole exome sequencing (WES) or array comparative genomic hybridisation. 
All legal guardians provided informed written consent for genetic testing in accordance with 
the respective national ethics guidelines and with approval of the local ethics committees in 
the participating study centres.
Variant classification
Variants in GRIN2B (NM_000834.3) were determined to be pathogenic, likely pathogenic 
or of unknown significance according to established guidelines of the American College of 
Medical Genetics (ACMG) (tables 1 and 2).15 All variants classified as (likely) pathogenic 
constitute de novo variants. The database of the Exome Aggregation Consortium (ExAC) 
served as the control population.16
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GRIN2B physiology
We used cDNA for wild-type (WT) human NMDA GluN1-1a (hereafter GluN1; 
NP_015566) and GluN2B subunits in pCI-neo (NP_000827.1).17 The mutant GluN2B 
constructs were generated by site-directed mutagenesis using the Quik-Change protocol 
(Stratagene). Synthesis and injection of cRNA into Xenopus laevis oocytes (Ecocyte Inc.) 
and two-electrode voltage-clamp current (TEVC) recordings were performed at −40 mV and 
23°C (unless otherwise stated), as previously described.18 Recording electrodes were filled 
with 0.3 M KCl for voltage electrode and 3 M KCl for the current electrode. The recording 
solution contained (in mM) 90 NaCl, 1 KCl, 10 HEPES, 0.5 BaCl2 and 0.01 EDTA (pH 7.4). 
The concentration-response curves were fitted with the following equations:
Equation 1
Equation 2
where nH is the Hill slope, EC50 is the concentration of the agonist that produces a half-
maximal effect, IC50 is the concentration of the antagonist that produces a half-maximal 
effect, and minimum is the degree of residual inhibition at a saturating concentration of the 
antagonist. The effects of co-application of increasing concentrations of memantine and 
maximally effective concentrations of glutamate (100 μM) and glycine (30 μM) on the 
response of NMDAR were determined using TEVC recordings from oocytes co-expressing 
GluN1 with the WT or the mutant GluN2B. The concentration-effect curves were recorded 
at a holding potential of −40 mV and fitted with equation 2.
Patient treatment
Patients were offered memantine treatment after functional confirmation of a gain-of-
function variant retaining memantine sensitivity in vitro. In four patients, oral memantine 
treatment was initiated aiming for doses of 0.5–0.6 mg/kg body weight per day referring to 
the dosage of a treatment trial in GRIN2A encephalopathy.19 Patients were neurologically 
assessed prior and during memantine treatment. Individual treatment trials were approved by 
the local ethics boards of the participating centres.
RESULTS
We evaluated 48 novel and all 43 previously published individuals with de novo GRIN2B 
variants. Overall, variants in 86 out of these 91 individuals were classified as pathogenic/
likely pathogenic. For 58 patients (39 novel and 19 published), detailed clinical data were 
available to comprehensively delineate the phenotypic spectrum of GRIN2B 
encephalopathy. The novel variant p.(Ser810Arg) was identified in monozygotic twin 
brothers with identical phenotype who were thus regarded as only one index case.
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Phenotypic spectrum
All patients carrying a (likely) pathogenic GRIN2B variant presented with DD, ID and/or 
ASD (86/86; 100%, table 1, table 2, detailed phenotypic data in online supplementary table 
3). The level of ID could be specified in 52 of 58 patients, with a majority displaying severe 
ID (31/52; 60%), whereas smaller proportions had moderate (13/52; 25%) or mild ID (8/52; 
15%). Autistic features were seen in 28% of patients (16/58). At the time of data 
ascertainment, about half of the patients have had seizures (30/58; 52%), with a variable age 
of onset ranging from birth to 9 years and the frequency of seizures varying from multiple 
per day to a few seizures per year. Patients presented with generalised seizures (18/30; 60%, 
mostly tonic or tonic-clonic), focal seizures (14/30; 47%) and/or epileptic spasms (11/30; 
37%). EEG patterns comprised hypsarrhythmia, focal, multifocal and/or generalised 
epileptiform activity. Follow-up data concerning seizure outcome were available for 22 
patients, with one half becoming seizure-free (11/22; 50%) and the other half remaining 
refractory to therapy. No obvious treatment strategy using conventional antiepileptic drugs 
(AED) was associated with a higher likelihood of seizure freedom. At least 31 patients 
displayed hypotonia (31/58; 53%), which required tube feeding in five patients (5/31; 16%). 
Spasticity was documented in 14 patients (14/58; 24%). In addition, six patients presented 
with dystonic, dyskinetic or choreiform movement disorders (6/58; 10%). Four patients 
(4/58; 7%) showed signs of developmental regression, two of whom were temporary and one 
case had recurrent regression. Microcephaly was seen in multiple patients (11/58; 19%) and 
cortical visual impairment (CVI) was reported in four (4/58; 7%), three of whom also had a 
malformation of cortical development (MCD).
Neuroimaging data
Neuroimaging was performed in 44 of 58 patients: six patients (6/44, 14%) showed a 
consistent MCD intermediate between typical polymicrogyria (PMG) and the cortical 
appearance of tubulinopathies, consisting of mixed large and small gyri separated by shallow 
sulci, a smooth grey-white border and little infolding (figure 1). These patients also had 
hypoplastic corpus callosum of varying degrees, enlarged and mildly dysplastic basal 
ganglia, hippocampal dysplasia with thick leaves and open hilus as well as enlarged tecta 
(figure 1A, E and M). One patient had no septum pellucidum (figure 1C). Generalised 
cerebral volume loss, compatible with cerebral atrophy, was described in four additional 
patients (4/44; 9%).
Genetic spectrum
The 86 (likely) pathogenic variants in GRIN2B comprise 52 distinct missense variants. 
Variants cluster within or in very close proximity to the ligand-binding domains S1 and S2, 
as well as transmembrane domains M1–M4 (figure 2A, table 1). The only variant escaping 
this clustering pattern is p.(Ile150Val) in the amino-terminal domain (ATD). Although most 
variants were unique, five variants occurred multiple times: p.(Arg540His), p.(Gly689Ser), 
p.(Arg696His), p.(Ile751Thr) and p.(Gly820Ala). The 21 distinct pathogenic variants 
presumably leading to truncation/haploinsufficiency comprised nonsense and frameshift 
variants (n=11), splice site variants (n=3), chromosomal rearrangements (n=3) as well as 
gross deletions encompassing only GRIN2B (n=4) (figure 2B, table 2). According to the 
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ACMG criteria, five de novo variants were classified as variants of unknown significance 
(see online supplement 2).15
Frequency of GRIN2B encephalopathy
Several of our collaborators (RSM, DS, CS and SB) performed different diagnostic panel 
sequencing approaches in 3136 independent epilepsy patients revealing seven (likely) 
pathogenic GRIN2B variants and a diagnostic frequency of 0.22%. Three diagnostic WES 
trio cohorts reported 8051 patients with neurodevelopmental disorders (defined as human 
phenotype ontology terms (1) abnormality of the nervous system, (2) multiple congenital 
anomalies, (3) seizures or (4) ASD.20–22 Overall, 15 pathogenic/likely pathogenic GRIN2B 
variants (14 missense, 1 frameshift) were identified, equalling a similar frequency of 0.19%. 
Expanding the data of the Deciphering Developmental Disorders Study,23 14 de novo 
missense variants in GRIN2B are significantly enriched (p value 2×10−17) in a combined 
cohort of WES trio data (n=8051) of patients with neurodevelopmental disorders (see online 
supplement 3). Among 209 independent individuals with PMG, we identified two patients 
with de novo GRIN2B variants.
Functional investigation
Seven of 17 variants evaluated showed small apparent currents (less than 15 nA for 1000 μM 
glutamate and 100 μM glycine) (see online supplementary table 1). Because it was unclear 
whether these small currents were agonist evoked, the properties of these variants could not 
be studied further. We assessed the pharmacological properties of NMDAR containing the 
remaining 10 GluN2B mutants. Three variants (p.(Ser541Arg), p.(Val558Ile), and p.
(Ile655Phe)) increased glutamate EC50 values (ie, decreased glutamate potency) by 6.7-fold, 
2.8-fold and 3.7-fold (table 3), indicating that higher concentrations of glutamate are needed 
to activate these receptors. The variant p.(Ser541Arg) increased glycine EC50 values by 2.9-
fold compared with WT receptors. Three variants (p.(Ser810Arg), p.(Met818Thr), and p.
(Al-a819Thr)) decreased both the glutamate and glycine EC50 values (ie, increased 
glutamate and glycine potency) (table 3), allowing these mutant receptors to be activated by 
lower concentration of agonists, suggesting a potential gain-of-function, provided trafficking 
and other features of receptor function are unchanged.
Voltage-dependent inhibition by extracellular Mg2+ and negative modulation by extracellular 
protons are two important features of NMDAR function. The voltage-dependent potency of 
Mg2+ inhibition showed that p.(Gly611Val) and p.(Ile655Phe) increased the Mg2+ IC50 
value from 25 μM for WT NMDAR to over 1000 μM and 220 μM for NMDAR containing 
GluN2B-Gly611Val and GluN2B-Ile655Phe, respectively (−60 mV holding potential; 
p<0.05, one-way analysis of variance) (table 3). Proton sensitivity was evaluated by 
comparing the current amplitude at two different extracellular pH values (6.8 vs. 7.6). Four 
mutant GluN2B subunits (p.(Ile655Phe), p.(Ser810Arg), p.(Met818Thr) and p.(Ala819Thr)) 
show significantly larger current response at pH 6.8 compared with pH 7.6 than WT 
receptors (table 3), suggesting that these variants significantly reduce tonic proton inhibition. 
This could result in more current flowing through the channel when the receptor is bound by 
agonists. Taken together, these data suggest that three variants (p.(Ser810Arg), p.
(Met818Thr) and p.(Ala819Thr)) are likely overactive under resting conditions as a result of 
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both the increased activation at low concentrations of agonists, reduced voltage-dependent 
Mg2+ block and reduced proton inhibition. The combination of these effects could 
potentially contribute to hyperexcitability and thus to patients’ epileptic phenotype. Further 
data are needed to determine how receptors with mixed functional changes (decreased 
agonist potency, decreased regulation by Mg2+ or protons) will alter, for example, charge 
transfer during synaptic transmission.
Evaluation of NMDAR antagonist memantine
The Food and Drug Administration-approved NMDAR antagonist memantine24 has been 
suggested to have anticonvulsant effects in some epilepsy animal models25 and was 
previously used off-label to effectively treat one patient with a gain-of-function GluN2A 
variant (p.(Leu812Met)).19 Thus, we evaluated its ability to inhibit six potential gain-of-
function GluN2B variants (p.(Gly611Val), p.(Asn615Ile), p.(Val618Gly), p.(Ser810Arg), p.
(Met818Thr) and p.(Ala819Thr))9 (see online supplementary figure 1 and supplementary 
table 2). The data indicated GluN2B-Gly611Val and GluN2B-Asn615Ile decreased 
memantine IC50 by 1.7-fold and 3-fold, respectively (ie, increased potency; 1.0 μM for p.
(Gly611Val) and 0.44 μM for p.(Asn615Il)e compared with 1.7 μM of WT). The other four 
variants (p.(Val618Gly), p.(Ser810Arg), p.(Met818Thr) and p.(Ala819Thr)) increased the 
IC50 values (ie, decreased potency) compared with WT (see online supplementary figure 1 
and supplementary table 2), suggesting that memantine can reduce NMDAR hyperactivity 
caused by these variants, although several mutants showed a reduced potency compared with 
WT receptors.
Targeted treatment with memantine
In four out of these six patients, we added memantine to the AED regimen (p.(Gly611Val), 
p.(Asn615Ile), p.(Val618Gly) and p.(Met818Thr)) (see online supplement 1). Parents and 
physicians initially observed beneficial effects such as improvements in awareness, 
behaviour and sleep. However, there were no changes in seizure frequencies and none of the 
potential benefits could be sufficiently objectivised. Long-term follow-up data were 
available in only one patient (p.(Val618Gly)) and did not suggest significant improvement.
DISCUSSION
We present the largest series of patients with (likely) pathogenic GRIN2B variants and 
provide a comprehensive review of the different aspects of GRIN2B encephalopathy. We 
strictly applied the ACMG criteria for variant classification to lessen the impact of potential 
biases caused by the heterogeneous collection of patients.
Phenotypic spectrum
In agreement with the known GRIN2B-associated features, our data confirm that all patients 
had DD and a majority developed severe ID, with autistic features in a quarter of patients. 
Half of the patients developed seizures with a broad heterogeneity with respect to age of 
onset, seizure semiology, EEG features and outcome. Expanding our previous observation, 
37% of patients presented with epileptic spasms.9 Less frequent findings of GRIN2B 
encephalopathy include generalised cerebral volume loss, CVI, hyperkinetic movement 
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disorders (dystonia, dyskinesia, chorea) and developmental regression. These features have 
been repeatedly observed in other GRIN-associated encephalopathies,451012192627 
suggesting a shared phenotypic spectrum, with differences likely reflecting variant class, 
location and effect in the various NMDAR subunits. However, we did not observe EEG 
patterns of continuous spikes and waves during sleep or centrotemporal spikes in our 
GRIN2B cohort, which appears to reflect a milder end of the GRIN spectrum that is so far 
predominantly associated with GRIN2A.28 As systematic genetic testing is more likely 
performed in patients with severe early-onset disorders, the mentioned frequencies of, for 
example, severe ID and epilepsy in GRIN2B encephalopathy are probably overestimated due 
to ascertainment bias.
Malformation of cortical development
Six patients presented with a consistent MCD intermediate between typical PMG and 
tubulinopathies. This has also been referred to as tubulinopathy-related dysgyria.29 Whereas 
tubulinopathies are classified as disorders of neuronal migration leading to cortical 
dysgenesis,30 PMG is considered to be due to postmigrational disruption of cortical 
development with fusion of cortical laminae.31 Knockdown of Grin2b in rat has been shown 
to disturb proper neuronal migration32 and glutamate has been implemented in its 
regulation.33 As GluN2B is predominantly expressed prenatally, disruption of neuronal 
migration seems to be the possible cause of GRIN2B-associated MCD. All six individuals 
had a very similar degree of severity and we did not observe less pronounced patterns of 
dysgyria in others. We can largely exclude the co-occurrence of, for example, known genetic 
tubulinopathies in all six cases, as individuals were screened by (trio)WES (n=4) or a panel 
targeting MCD genes (n=2). Other than in GRIN2B, we did not identify any other putatively 
causative variants in all six cases. Deficient ion channels are known to cause a plethora of 
human neurodevelopmental disorders, with the exception of abnormal cell migration. 
Despite the observation of six patients with pathogenic SCN1A variants who also had focal 
cortical dysplasia or bilateral periventricular nodular heterotopia,34 the identification of six 
unrelated individuals with (likely) pathogenic variants in GRIN2B and a consistent MCD 
expands the phenotypic spectrum and reveals novel phenotypic consequences of 
channelopathies.
Genetic spectrum
GRIN2B is a gene with a significantly reduced number of missense variants in controls, 
indicating a selective constraint.16 All (likely) pathogenic missense variants cluster within or 
in direct proximity to ligand-binding sites and transmembrane domains. These regions are 
largely spared by (likely) benign single nucleotide variants (SNV) in ExAC controls, 
suggesting that missense variants within these functionally important and conserved 
domains are only scarcely tolerated.3536 In contrast, the ATD and carboxy-terminal domain 
(CTD), as well as two small segments within S1 and M1, are markedly enriched for (likely) 
benign SNV in controls. The likely pathogenic missense variant p.(I-le150Val) escapes this 
clustering pattern, as it is located within a stretch of ~300 bp that contains very few missense 
variants within the ATD. It remains unclear whether or not this variant alters subunit 
assembly, ligand-binding or allosteric regulation by extracellular Zn2+.12
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The ratio of expected versus observed numbers of truncating variants of 33.9:0 in controls 
and the probability of loss-of-function intolerant score of 1.00 suggest that GRIN2B 
haploinsufficiency is most likely not tolerated.16 We observed seven truncating variants in 
the CTD establishing a premature termination codon in the last exon and therefore likely 
escaping nonsense-mediated mRNA decay and possibly not significantly altering protein 
function1537: two de novo truncating variants in patients with ID,20 one de novo frameshift 
variant in a healthy control individual38 and four frameshift variants reported in ExAC. The 
ExAC-annotated frameshift variant c.99dupC, p.(Ser34Glnfs*25) occurring in 27 controls 
conflicts with the hypothesis of haploinsufficiency. However, this variant is part of a 
homopolymer stretch of seven recurrent C nucleotides, raising the suspicion of a technical 
artefact despite having been described as pathogenic de novo variant via different 
sequencing approaches in an individual with ASD.39
Genotype-phenotype correlations
MCD-associated variants are located in the transmembrane domain M3 (p.(Ala636Val), p.
(Ala639Val) and p.(Ile655Phe)), in the ligand-binding domain S2 (p.(Arg693Ser)) or within 
the linker domain connecting S2 and M4 (p.(Ser810Arg) and p.(Ser810Asn)). Both missense 
variants at position 810 (p.(Ser810Arg) and p. (Ser810Asn)) were associated with MCD, 
whereas position 636 also showed two different (likely) pathogenic missense variants, with 
only p.(Ala636Val) being seen in MCD.40 Thus, the specific functional mechanisms 
mediating MCD still remain to be elucidated. In contrast to our previous hypothesis,9 we did 
not find a significant correlation between variant class (missense vs truncation) and 
occurrence of seizures (Fisher’s exact test, p=0.1187). However, there was a significant 
correlation between variant class and intellectual outcome (mild-moderate vs severe ID) 
(Fisher’s exact test, p=0.0079), with truncation carriers tending to present with mild or 
moderate instead of severe ID.
Functional investigation
We evaluated several different aspects of receptor function, as it is possible that variants 
could have opposing effects on receptor activity (eg, Ile655Phe). We found that several other 
variants (Ser810Arg, Met818Thr, Ala819Thr) showed multiple differences in their 
properties that each enhanced NMDAR function, suggesting a potential gain-of-function of 
NMDAR assuming there is no change in the fraction of receptors that reach the cell surface 
or synapse. Such functional changes could lead to excito-toxic cell death, circuit rewiring, 
changes in neuronal migration or persistent increases in excitatory synaptic and non-synaptic 
drive through surface receptors. Thus there are multiple ways these variant receptors could 
contribute to clinical symptoms. Extensive functional analyses of rare variants in the 
GluN2B agonist binding domain recently showed the multifaceted and sometimes 
conflicting consequences that these variants can have on NMDAR activity.36
Targeted treatment with memantine
Initial subjective improvements in awareness, behaviour and sleep could not be sufficiently 
objectivised, and seizure frequencies showed no significant changes. In three cases, the 
missense variant led to significant loss of Mg2+ block engaging a different mechanism 
compared with the multiple means by which channel function was enhanced in a patient 
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with p.(Leu812Met) in GRIN2A, which responded favourably to memantine treatment.19 In 
comparison, the variant of the fourth individual (p.(Met818Thr)) displayed similarities with 
respect to, for example, the increased glycine and glutamate potency of the NMDAR; 
however this does not hold true for patients’ treatment response to memantine. At present, it 
remains entirely unclear whether memantine is effective at all in this patient population and 
what factors (eg, variant location, mechanism of gain-of-function, patient age, memantine 
dose, differences in blood and brain concentrations) might influence memantine treatment 
response. Although some variants retain sensitivity to channel blockers like memantine in 
vitro, translating these potential benefits into patient care still remains elusive. Options for 
personalised therapy in GRIN2B encephalopathy still require more systematic and thorough 
evidence best through double-blinded prospective trials with a homogeneous patient 
population in terms of variant class.
Summary
Given the frequency of about 0.2% among individuals with neurodevelopmental disorders 
and/or childhood-onset epilepsy, GRIN2B encephalopathy appears to be a recurrent and 
distinct diagnosis. Our observations of novel features expand the phenotypic spectrum and 
suggest novel consequences of channelopathies resulting in disturbed neuronal migration. 
We found phenotypic similarities and a marked clustering of missense variants in ligand-
binding and transmembrane domains paralleling other GRIN-associated disorders. Despite 
the limited conclusions regarding treatment with memantine in four patients with potential 
gain-of-function variants, the diverse functional consequences of (likely) pathogenic variants 
possibly enable future personalised therapeutic approaches in patients with GRIN2B 
encephalopathy.
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Figure 1. 
MRI of patients with malformation of cortical development. MRI scans of patients p.
(Ala639Val) (A–D), p.(Ser810Arg) (E–H), p.(Ile655Phe) (I–L), p.(Ala636Val) (M–P), p.
(Arg693Ser) (Q–T), p.(Ser810Asn) (U–X), and a normal control (AA-DD) showing T1-
weighted mid-sagittal images (first column), T2-weighted axial images through the basal 
ganglia (second column) and higher lateral ventricles (third column), and T2-weighted 
coronal images through the hippocampus (fourth column). The mid-sagittal images are 
normal except for mildly low forehead in several subjects (A, I, U), although several are 
slightly off the midline. The lower axial images show relatively large and mildly dysplastic 
basal ganglia compared with normal (asterisks in B, (F, J, N, R and V)). All axial images 
Platzer et al. Page 17
J Med Genet. Author manuscript; available in PMC 2017 October 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(middle two rows) show a diffuse irregular gyral pattern with small gyri and limited 
intracortical microgyri (white arrows on the right side of images that point to the left 
hemispheres), an appearance intermediate between typical polymicrogyria and the cortical 
appearance of tubulinopathies. The coronal images show hippocampal dysplasia with thick 
leaves and open hilus, which varies from severe (D, H, X) to moderate (L, P).
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Figure 2. 
De novo variants in GRIN2B. (A) Clustering of (likely) pathogenic missense variants in 
GRIN2B. All but one of the (likely) pathogenic missense variants cluster in the ligand-
binding or transmembrane domains of GluN2B, which are regions with little to no benign 
missense variation in the control population. The de novo missense p.(Arg1111His) and the 
inframe deletion p.(Lys976del) in the CTD were classified as VUS. (B) Location of 
pathogenic truncating variants in GRIN2B. The recurrent variant c.99dupC, p.
(Ser34Glnfs*25) listed in ExAC is part of a homopolymer stretch of seven recurrent C 
nucleotides suggesting a technical artefact. Variants classified as VUS establish a premature 
termination codon in the last exon of GRIN2B, including a de novo truncating variant in a 
control individual p.(Arg1099Alafs*51).38 Red bars indicate pathogenic/likely pathogenic 
de novo variants. Blue bars indicate de novo VUS. Grey bars indicate single nucleotide 
variants (SNV) listed in one ExAC individual each. Black bars indicate SNV seen in more 
than one ExAC individual. ATD, amino-terminal domain; CTD, carboxy-terminal domain; 
ExAC, Exome Aggregation Consortium; M1–M4, transmembrane domain; S1, S2, ligand-
binding domain; VUS, variants of unknown significance.
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Table 3
Summary of pharmacological data
Glu, EC50, μM (n) Gly, EC50, μM (n) Mg2+, IC50, μM (n)* Proton, IpH6.8/IpH7.6% (n)
WT 2B 1.5±0.08 (44) 0.35±0.02 (41) 25±2.7 (33) 15%±0.5% (47)
S541R 10±1.7 (10)† 1.0±0.15 (9)† 18±1.8 (9) 17%±0.4% (13)
V558I 4.2±0.8 (6)† 0.50±0.03 (6) 26±6.2 (6) 13%±0.2% (6)
G611V 1.7±0.1 (8) 0.33±0.02 (6) >1000 (8)† 11%±0.4% (8)
I655F 5.6±0.60 (7)† 0.51±0.07 (6) 220±36 (6)† 67%±2.6% (10)†
M706V 1.5±0.18 (7) 0.24±0.02 (6) 26±4.8 (5) 16%±1.2% (6)
S810R 0.013±0.003 (8)† 0.027±0.03 (7)† 24±3.3 (5) 35%±4.2% (8)†
M818T 0.37±0.07 (10)† 0.09±0.02 (6)† 29±8.0 (8) 47%±4.1% (8)†
A819T 0.58±0.07 (9)† 0.09±0.02 (6)† 36±4.9 (9) 51%±1.4% (6)†
G820A 1.6±0.23 (6) 0.35±0.04 (8) 21±4.8 (7) 10%±0.21% (6)
L825V 1.3±0.2 (9) 0.36±0.07 (5) 35±3.6 (10) 14%±0.7% (8)
Mean±SEM (n).
The log of the EC50 and IC50 are normally distributed and were used in all statistical tests.
*
Holding at −60 mV.
†p<0.05 compared with corresponding wild-type (WT): one-way analysis of variance, Tukey post-hoc.
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